73: Tyrosine kinase inhibitors (TKIs) as first-line treatment for advanced EGFR mutated non-small cell lung cancer (NSCLC): a single-centre experience. (January 2017) - Buckley, H.; Ralph, A.; Liu, H.; Gilligan, D.; Harden, S.